<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sulfiredoxin (Srx) is the enzyme that reduces the hyperoxidized inactive form of peroxiredoxins </plain></SENT>
<SENT sid="1" pm="."><plain>To study the function of Srx in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> in vivo, we tested whether loss of Srx protects mice from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development </plain></SENT>
<SENT sid="2" pm="."><plain>Srx null mice were generated and colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> was induced by an azoxymethane (AOM) and <z:chebi fb="0" ids="34674">dextran sulfate</z:chebi> <z:chebi fb="199" ids="26708">sodium</z:chebi> (DSS) protocol </plain></SENT>
<SENT sid="3" pm="."><plain>Compared with either <z:mp ids='MP_0002169'>wild-type</z:mp> (Wt) or heterozygotes, Srx(-/-) mice had significantly reduced rates in both <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> multiplicity and volume </plain></SENT>
<SENT sid="4" pm="."><plain>Mechanistic studies reveal that loss of Srx did not alter <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell proliferation; however, <z:mp ids='MP_0006042'>increased apoptosis</z:mp> and decreased inflammatory cell infiltration were obvious in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from Srx null mice compared with those from Wt control </plain></SENT>
<SENT sid="5" pm="."><plain>In addition to the AOM/DSS model, examination of Srx expression in human reveals a tissue-specific expression pattern </plain></SENT>
<SENT sid="6" pm="."><plain>Srx expression was also demonstrated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients and the levels of expression were associated with patients' clinic stages </plain></SENT>
<SENT sid="7" pm="."><plain>These data provide the first in vivo evidence that loss of Srx renders mice resistant to AOM/DSS-induced colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, suggesting that Srx has a critical oncogenic role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development, and Srx may be used as a marker for human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> pathogenicity </plain></SENT>
</text></document>